Tevogen Bio (TVGN) to Release Earnings on Wednesday

Tevogen Bio (NASDAQ:TVGN) is projected to release its results before the market opens on Wednesday, February 25th. Analysts expect Tevogen Bio to post earnings of ($0.03) per share for the quarter.

Tevogen Bio Trading Down 6.1%

TVGN stock opened at $0.28 on Friday. The company has a market capitalization of $55.79 million, a P/E ratio of -1.48 and a beta of -0.80. The firm has a 50 day simple moving average of $0.33 and a 200-day simple moving average of $0.57. Tevogen Bio has a twelve month low of $0.23 and a twelve month high of $1.54.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on TVGN shares. D. Boral Capital cut their target price on shares of Tevogen Bio from $10.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, November 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $5.00.

Hedge Funds Weigh In On Tevogen Bio

Several hedge funds have recently made changes to their positions in the business. Bridgeway Capital Management LLC raised its holdings in shares of Tevogen Bio by 66.7% in the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after purchasing an additional 33,000 shares in the last quarter. Deutsche Bank AG lifted its stake in Tevogen Bio by 304.1% during the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after purchasing an additional 130,738 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Tevogen Bio by 126.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after buying an additional 152,572 shares in the last quarter.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.